• 76 patients enrolled
•
Emory Healthcare newest trial site addition (Tigris site #20) enrolling out of two hospitals.University of California San Francisco (UCSF) andUniversity of Alabama at Birmingham (UAB) continue to be strong Tigris enrollers, with the enrollment of patients 75 and 76 at the end of October.- 76 patients enrolled to date and continuing to close in on the interim target of 90 patients, an important milestone as the Company’s strategic commercial partner,
Baxter (NYSE:BAX), will have the opportunity to view the data as well as provide a second milestone payment to Spectral. - Crude 28-day mortality results, thus far, continue to exceed efficacy targets.
Dr.
“We are taking measured, yet rapid action to maintain and even increase momentum in patient enrollment with a view to enrolling our interim count of 90 patients, which is expected to play as a major catalyst for the Company,” said
About Spectral
Spectral is a Phase 3 company seeking
PMX is approved for therapeutic use in
Spectral is listed on the
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the company’s ability to raise capital and the availability of funds and resources to pursue R&D projects, the recruitment of additional clinical trial sites, the rate of patient enrollment, the successful and timely completion of clinical studies, the success of Baxter’s commercialization efforts, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
For further information, please contact:
Capital Markets & Investor Relations | US Investor Relations |
416-962-3300 | 212-671-1020 |
am@spinnakercmi.com | edt@crescendo-ir.com |
CFO | |
416-626-3233 | |
bmcinnis@spectraldx.com |
Source:
2023 GlobeNewswire, Inc., source